Drug discovery company Confo Therapeutics has appointed John Edward Berriman as non-executive director and chairman of the board of directors. Berriman is set to take his seat on the board December 21.
Spanish world market leader for nucleic acid-based virus screening in blood banks, Grifols, has confirmed the purchase price for US-based Hologic’s NAT donor screening unit.
Antifungal drug developer F2G Ltd has appointed distinguished research scientist John Rex to the position of Chief Medical Officer.
At the beginning of October, Isabel De Paoli assumed the position of Chief Strategy Officer at German healthcare company Merck GmbH. She will head the Group Strategy and Transformation Function, which has just been created.
Finnish theranostics specialist Orion Corporation is set to fill its oncology pipeline through a drug development alliance.
Dutch-German molecular diagostics specialist Curetis has bagged debt finanancing from the European Investment Bank (EIB) to expand its automated multiplex PCR platform Univero. The company will receive €10m immediately. Further €15m are milestone-dependent.
In order to prepare for the start of Phase III trials with its lead drug candidate Nefecon, Pharmalink AB has made several new appointments. Among them Kari Sandvold, who will take over as Vice President Pharmaceutical Development and Manufacturing.
While competitor Eli Lilly has abandoned commercialisation of its Alzheimer’s therapy solanezumab due to lack of efficacy in a pivotal Phase III study, Genentech has tabled data supporting further development of its Phase III drug crenezumab. The anti-Abeta antibody is highly homologous to solanezumab.
Copenhagen-based Symphogen is losing its long-time CEO Kirsten Drejer, who co-founded the Danish antibody specialist in 2000. In her place, erstwhile CFO Martin Olin is taking over the helm.
French immunotherapy company TxCell has teamed up with Inserm Transfert, the tech transfer subsidiary of the French National Institute of Health and Medical Research Inserm, to develop immuno-suppressive regulatory T cells.